Figure 5. NOD2 in myeloid cells is required for Efm-mediated protection.

A-L) DSS-treated Nod2^fl/fl;LysM-Cre⁻ and Cre⁺ mice (A-F) or Nod2^fl/fl;Villin-Cre⁻ and Cre⁺ mice (G-L) following administration of Efm or control were examined for Efm burden in stool (A and G), survival (B and H), changes in body weight (C and I), disease score (D and J), fecal LCN2 (E and K), and colon length on day 23 (F and L). Lines in A and G and data points in F, K, and L represent Individual mice. Data points in C-E, I, and J represent mean ± SEM. Bars represent mean ± SEM from at least three independent experiments. Indicated p values by log-rank Mantel-Cox test in B and H, two-way ANOVA test in C, D, I, and J, and unpaired t test, two-tailed in F, K, and L.